M&A Deal Summary

Forest Laboratories Acquires Cerexa

On January 1, 2007, Forest Laboratories acquired life science company Cerexa from EGS Healthcare Capital Partners and Montreux Equity Partners for 480M USD

Acquisition Highlights
  • This is Forest Laboratories’ 1st transaction in the Life Science sector.
  • This is Forest Laboratories’ 4th largest (disclosed) transaction.
  • This is Forest Laboratories’ 1st transaction in the United States.
  • This is Forest Laboratories’ 1st transaction in California.

M&A Deal Summary

Date 2007-01-01
Target Cerexa
Sector Life Science
Buyer(s) Forest Laboratories
Sellers(s) EGS Healthcare Capital Partners
Montreux Equity Partners
Deal Type Add-on Acquisition
Deal Value 480M USD

Target

Cerexa

Oakland, California, United States
website
Cerexa, Inc. was a privately held specialty pharmaceutical company, created as a spin-out from the sale of Peninsula Pharmaceuticals to Johnson & Johnson, focused on developing and commercializing novel anti-infective therapies for the treatment of life-threatening infections.

Search 190,634 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Forest Laboratories

New York, New York, United States

website


Category Company
Founded 1956
Sector Medical Products
Employees5,800
Revenue 3.1B USD (2013)
DESCRIPTION

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe.


DEAL STATS #
Overall 1 of 4
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 4
State (California) 1 of 1
Country (United States) 1 of 3
Year (2007) 1 of 1
Size (of disclosed) 4 of 4
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-04-14 Clinical Data

Newton, Massachusetts, United States

Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics.

Buy $1.2B

Seller(S) 2

SELLER

EGS Healthcare Capital Partners

Rowayton, Connecticut, United States

website


Category Private Equity Firm
Founded 1999
PE ASSETS 135M USD
Size Small
Type Sector Focused
DESCRIPTION

EGS Healthcare Capital Partners is a specialist private equity firm focused on investments in the healthcare sector. Specific areas of interest include biotechnology, specialty pharmaceutical, and medical device companies. EGS typically invests in late-stage private and emerging public companies with promising products. EGS prefers to lead investments with an initial commitment of $5 million per transaction. The Firm generally seeks board representation. EGS Healthcare Partner was formed in 1999 and is based in Rowayton, Connecticut.


DEAL STATS #
Overall 4 of 7
Sector (Life Science) 3 of 5
Type (Add-on Acquisition) 2 of 3
State (California) 2 of 3
Country (United States) 4 of 6
Year (2007) 1 of 3
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-06-30 Peninsula Pharmaceuticals

Alameda, California, United States

Peninsula Pharmaceuticals, Inc. is a pharmaceutical company focuses on licensing, developing, and commercializing anti-infective products for the treatment of life-threatening infections.

Sell $245M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-04-20 Endius

Plainville, Massachusetts, United States

Endius, Inc. is a privately held medical device company that had developed and commercialized a minimally invasive access system for spine surgery.

Sell $80M
DESCRIPTION

Montreux Equity Partners is a growth investment firm focused on investing in commercial stage companies with category leading products, technologies, and services. Montreux Equity Partners looks to invest $10 to $20 million in fast growing companies with $5 to $50 million in revenue. Montreux Equity Partners was formed in 1993 and is headquartered in San Francisco, California.


DEAL STATS #
Overall 7 of 24
Sector (Life Science) 3 of 9
Type (Add-on Acquisition) 7 of 15
State (California) 7 of 22
Country (United States) 7 of 24
Year (2007) 1 of 4
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-11-22 OREXIGEN Therapeutics

La Jolla, California, United States

Orexigen Therapeutics, Inc. is a bio-pharmaceutical company focuses on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA.

Buy $30M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-02-08 NeurogesX

San Mateo, California, United States

NeurogesX, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life. NeurogesX was founded in 1998 and is based in San Mateo, California.

Sell -